The Novel Plk Inhibitor Volasertib Overcomes Cytarabine Resistance in Acute Myeloid Leukemia

被引：0
|
作者：
Fu, Shuang [1 ]
Kelly, Kevin R. [2 ]
Espitia, Claudia M. [3 ]
Han, Yingchun [1 ]
Carraway, Hetty E. [4 ]
Advani, Anjali S. [4 ]
Maciejewski, Jaroslaw P. [4 ]
Sekeres, Mikkael A. [4 ]
Steffan, Nawrocki T. [3 ]
Carew, Jennifer S. [1 ]
机构：
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Univ So Calif, Los Angeles, CA USA
[3] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[4] Cleveland Clin, Cleveland, OH 44106 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development
    Janning, Melanie
    Fiedler, Walter
    FUTURE ONCOLOGY, 2014, 10 (07) : 1157 - 1165
  • [42] Molecular Targeting of the Oncoprotein PLK1 in Pediatric Acute Myeloid Leukemia: RO3280, a Novel PLK1 Inhibitor, Induces Apoptosis in Leukemia Cells
    Wang, Na-Na
    Li, Zhi-Heng
    Zhao, He
    Tao, Yan-Fang
    Xu, Li-Xiao
    Lu, Jun
    Cao, Lan
    Du, Xiao-Juan
    Sun, Li-Chao
    Zhao, Wen-Li
    Xiao, Pei-Fang
    Fang, Fang
    Su, Guang-Hao
    Li, Yan-Hong
    Li, Gang
    Li, Yi-Ping
    Xu, Yun-Yun
    Zhou, Hui-Ting
    Wu, Yi
    Jin, Mei-Fang
    Liu, Lin
    Ni, Jian
    Wang, Jian
    Hu, Shao-Yan
    Zhu, Xue-Ming
    Feng, Xing
    Pan, Jian
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (01): : 1266 - 1292
  • [43] Guided by a predictive ex vivo test: Bringing the PLK1 inhibitor volasertib back into the clinic for venetoclax-HMA relapsed/refractory acute myeloid leukemia patients
    Lacher, Markus Daniel
    Michelson, Glenn
    Ling, Allen
    Anderson, Wade
    Vinas, Jeaneille
    Gu, Christine J.
    Leonardi, Chris
    Wagner, Joseph
    Mannis, Gabriel N.
    CANCER RESEARCH, 2024, 84 (06)
  • [44] GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia
    Xinhua Xiao
    Peihong Wang
    Weina Zhang
    Jiayi Wang
    Mansi Cai
    Hua Jiang
    Yingli Wu
    Huizhuang Shan
    Cancer Cell International, 23
  • [45] GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3-ITD acute myeloid leukemia
    Xiao, Xinhua
    Wang, Peihong
    Zhang, Weina
    Wang, Jiayi
    Cai, Mansi
    Jiang, Hua
    Wu, Yingli
    Shan, Huizhuang
    CANCER CELL INTERNATIONAL, 2023, 23 (01)
  • [46] Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine
    Belén P. Solans
    Angèle Fleury
    Matthias Freiwald
    Holger Fritsch
    Karin Haug
    Iñaki F. Trocóniz
    Clinical Pharmacokinetics, 2018, 57 : 379 - 392
  • [47] Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine
    Solans, Belen P.
    Fleury, Angele
    Freiwald, Matthias
    Fritsch, Holger
    Haug, Karin
    Troconiz, Inaki F.
    CLINICAL PHARMACOKINETICS, 2018, 57 (03) : 379 - 392
  • [48] Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia
    Kobayashi, Yukio
    Yamauchi, Takahiro
    Kiyoi, Hitoshi
    Sakura, Toru
    Hata, Tomoko
    Ando, Kiyoshi
    Watabe, Aiko
    Harada, Akiko
    Taube, Tillmann
    Miyazaki, Yasushi
    Naoe, Tomoki
    CANCER SCIENCE, 2015, 106 (11) : 1590 - 1595
  • [49] Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
    Xu, Xi
    Ma, Weiwei
    Qiu, Guo
    Xuan, Li
    He, Chong
    Zhang, Tian
    Wang, Jian
    Liu, Qifa
    BIOLOGY-BASEL, 2023, 12 (10):
  • [50] Zoledronic acid overcomes adriamycin resistance in acute myeloid leukemia cells by promoting apoptosis
    Fan, Rui-Fang
    Chen, Yu-Xin
    Fang, Zhi-Gang
    Guo, Xiao-Yan
    Lu, Ying
    Liu, Ling-Ling
    Xu, Yi-Chuan
    Liu, Xiang-Fu
    Lin, Dong-Jun
    MOLECULAR MEDICINE REPORTS, 2016, 14 (06) : 5660 - 5666
12345